Jaguar Health (NASDAQ:JAGX) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Stock Up 15.6 %

NASDAQ JAGX opened at $0.21 on Tuesday. The company has a 50 day moving average of $0.10 and a 200-day moving average of $0.18. Jaguar Health has a 1-year low of $0.05 and a 1-year high of $1.22. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.